AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

COPD Mucus: An Overlooked Barrier to Better Outcomes

3:15 pm - Tuesday 15th September 2026

Airway mucus plugs are associated with COPD disease progression, exacerbations and mortality
Mucolyitcs borrowed from experience in Cystic Fibrosis are not effective
A more comprehensive understanding of mucus plug formation is leading to development of new approaches to removing mucus plugs

Larry Lands

Chief Medical Officer

CILA Therapeutics